The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
 
Catriona Harvey
No Relationships to Disclose
 
Kazi Jannatun Nahar
No Relationships to Disclose
 
Serigne N. Lo
No Relationships to Disclose
 
Tasnia Ahmed
No Relationships to Disclose
 
Sheima Farag
No Relationships to Disclose
 
Nadia Yousaf
No Relationships to Disclose
 
Kate Young
Research Funding - AstraZeneca/Merck (Inst); Bristol-Myers Squibb (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Merck; Lilly
 
Liselotte Tas
No Relationships to Disclose
 
Aafke Meerveld-Eggink
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Austin Thomas
No Relationships to Disclose
 
Jennifer Leigh McQuade
Honoraria - Bristol-Myers Squibb/Roche; Merck
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck
 
Bastian Schilling
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pfizer/EMD Serono; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi Aventis GmbH
Research Funding - Novartis (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Janssen; Merck; Mosaic ImmunoEngineering; Novartis; Oncosec; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Roberto Martin Huertas
No Relationships to Disclose
 
Ana Maria Arance
Consulting or Advisory Role - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - BMS (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Novartis; Pierre Fabre
 
Joanna Lee
No Relationships to Disclose
 
Lisa Zimmer
Stock and Other Ownership Interests - Bayer
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi; Sun Pharma
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche